Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Advances in Wound Care aims to fill a gap in bridging the different disciplines necessary to support wound research and care. It provides an unique forum for the field of tissue injury and repair, with an emphasis on acute and chronic skin wound care to optimize patient outcomes. The Journal enables rapid dissemination of translational research from bench to bedside, with wound care applications including burns, major trauma, blast injuries, surgery, diabetic ulcers, ostomy, bedsores, and more. Advances in Wound Care supports public-academia-private partnership, the success of which is critical to improve wound care outcomes.
Advances in Wound Care welcomes review articles, both short critical treatise as well as comprehensive. The Technology Advances track is dedicated to addressing product development for clinical care as well as to novel methodologies for research advancement. The News and Views track will report newsworthy developments in the wound care community. Discovery Express will rapidly publish short original research articles of outstanding importance. For this track, submission to first decision time will not exceed 2 weeks!
Click here to review Advances in Wound Care standard journal policies on peer review, ethic statement(s), data sharing, authorship, conflict of interest, copyright and Open Access, fees, as well as post-publication corrections/retractions and definitions of scientific misconduct.
All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.
Online submission: Advances in Wound Care will only consider manuscripts that are submitted through our online peer-review website:
Once a manuscript is successfully submitted, the submitting author should expect to receive an email notification within hours. Only senior authors of a work who take complete scientific as well as financial responsibility of a submission may submit the work. Manuscripts cannot be submitted on behalf of the corresponding author by any agent other than the corresponding author's own office.
Cover Letter: The submitting author must accept responsibility for the following:
- The submitting author has the written consent from all authors to submit the manuscript and that all authors accept complete responsibility for the contents of the manuscript.
- The manuscript has not been previously published, or is not currently under consideration elsewhere, and that the work reported will not be submitted for publication elsewhere until a final decision has been made as to its acceptability by Advances in Wound Care (note that posting of submitted material on a website is considered pre-publication).
- The manuscript is truthful original work.
Advances in Wound Care publishes all accepted papers within 72 hours of acceptance in their unedited, uncorrected format. It is important to note that the information that is published online, and in all indexing services, is pulled directly from the data that is populated into the fields in Manuscript Central – NOT from the manuscript file – when the paper is originally uploaded to the system for peer review. Consequently, any errors contained in the system will remain on our website and all indexing services, including Medline, until the next revision* of the article is published. It is critical that submitting agents enter all authors’ names correctly into the system at the time of submission. Any errors within the manuscript will remain on our website until the subsequent online version is published.
*The next revision will take place after the corresponding author sees page proofs, makes any necessary corrections, and returns the changes to the Publisher. Once the alterations are completed, the revised version will be published on our website, and the newly corrected information will then be released to Medline/PubMed, in addition to any other indexing services in which the Journal is included.
Please note that the typical time between acceptance of a paper and page proof distribution is approximately 4-8 weeks depending on the length and complexity of the paper.
Please upload individual files of all manuscript material—do NOT upload a single PDF file containing all text, figure, and table files of your article. Once all individual files are uploaded on to Manuscript Central, the system will automatically create a single PDF proof for you and the peer-review process.
Peer Review Process
Format. Manuscripts that are not formatted strictly according to the guidelines described herein or in the guide for Online Submission will be administratively rejected without any peer review.
Keywords (Areas of Expertise)
To facilitate the peer review process, select 4-6 keywords from the drop-down list of pre-selected terms when submitting your manuscript. These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.
Science. Advances in Wound Care can only accept highly competitive articles. All submissions, other than those in the News and Views track, are subject to peer review.
Critical Reviews: Articles in this track should address late-breaking science in a focused area relevant to wound healing and care. Critical Reviews should range from 3,000 to 4,000 words (excluding a maximum of 50 references and figure legends) with at least 6 illustrations.
Technology Advances: Covers novel technologies related to wound care product development or wound healing research methodology.
Discovery Express: Aimed at rapid communication of short original articles. Two-week (average) peer review to decision. 3,000 word limit, excluding methods, figure legends, references, and abstract; maximum of 40 references; no more than 6 figures or tables.
News and Views: Covers case observations of extraordinary significance and newsworthy developments in the wound care community. May include: review of patents and other relevant intellectual properties, business of wound care, law, insurance, billing, global issues, ethics, quality control, special considerations and so on. News and Views articles should not exceed a total of 1,500 words, excluding a maximum of 9 references. Photos may be included as part of illustration.
Comprehensive Invited Reviews: Written by invited authoritative experts. Comprehensive Invited Reviews are to be between 5,000 and 7,500 words long (excluding a maximum of 150 references and figure legends) and must include at least 10 illustrations. If you are an authoritative expert (senior investigator with long standing and extensive publication record) in a field relevant to the Journal and are interested in contributing a Comprehensive Invited Review article, please write to the Editor-in-Chief. These articles are intended to be full-length critical appraisals of topics that would be of long-term archival value. Textbook-style coverage is strongly discouraged. Emphasis should be placed on late-breaking advances and critical treatment. Advances in Wound Care dedicates a substantial amount of space to these articles. To ensure balanced treatment of any given subject, these articles are typically reviewed by several experts in that field. These experts are identified in the publication as Reviewing Editors unless they opt against it.
PLAGIARISM DETECTION SOFTWARE
All accepted manuscripts will be processed through plagiarism detection software, and any notice of acceptance is considered conditional, pending the review and verification of the plagiarism detection report. If the report detects a high incidence of overlap in text, the Editor-in-Chief reserves the right to rescind the decision to accept the paper.
ETHICAL CONSIDERATIONS IN THE CONDUCT AND REPORTING OF RESEARCH:
PROTECTION OF HUMAN SUBJECTS AND ANIMALS IN RESEARCH
Patients and Study Participants
All manuscripts must comply with the privacy and confidentiality requirements outlined on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit http://www.icmje.org/recommendations/browse/roles-and-responsibilities/protection-of-research-participants.html
When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study. Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki. In the Methods section, state that informed consent was obtained from subjects (specify written or verbal).
The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee(s), and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.
In addition, text and photographs should not reveal any identifying information unless it is essential for scientific purposes (in which case, consent should be obtained). Masking the subjects’ eyes in photographs is often insufficient to protect their identity.
PUBLICATION ETHICS AND MALPRACTICE STATEMENT
Study Design and Ethics
Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.
Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.
Definitions of Scientific Misconduct
Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).
Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:
- Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
Material failure to comply with legislative and regulatory requirements affecting research:
Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
- Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
- Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
- Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.
Responding to Allegations of Possible Misconduct
The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.
When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.
If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.
All allegations will be kept confidential.
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.
Upon acceptance of any manuscript, EACH author listed on a paper will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications, particularly the Copyright Agreement.
FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION.
The corresponding author is responsible for communicating with coauthors to make sure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.
PREPARATION OF MANUSCRIPT
Type the entire manuscript, including figure legends, tables, and references, double-spaced using Microsoft Word. Leave 1-inch margins on all sides. Manuscripts should be written succinctly and should cite select references that are directly relevant. For guidance on length of each article, see section on article types above. Manuscripts not following these length related guidelines will be subjected to administrative rejection.
Title page: Specify the type of article. Title page must list the full title of the article; author(s); all authors’ full affiliations; an abbreviated title for the running head (not to exceed 50 characters, including spaces); name and address of corresponding author, contact telephone, fax number, and e-mail address. Where necessary, identify each author’s affiliation by superscript numbers matched to the appropriate institution. Please list word count (excluding abstract, references, and figure legends). Manuscript keywords (search terms): On the title page of the manuscript, include a minimum of three (3), maximum of six (6), search terms that will aid in the discoverability of the article in indexing services and search engines. These terms may or may not be different from the terms you selected for the peer review process and areas of expertise. You will be asked to retype these search terms in the submission form when uploading your manuscript. These keywords will be included in the published article. If the search terms entered do not match the manuscript, the manuscript will serve as the default.
Second page: Provide an abstract of no more than 250 words. For Review articles, the abstract should consist of the following sections: Significance, Recent Advances, Critical Issues, and Future Directions. For Discovery Express and Technology Advances articles, the abstract should consist of the following sections: Objective, Approach, Results, Innovation, and Conclusion. For News and Views articles, the abstract does not need to be structured with headings. Submissions with abstracts longer than 250 words will not be considered for publication.
Following pages (Discovery Express and Technology Advances): The abstract should be followed by the following sections: Introduction, Clinical Problem Addressed (even if it is basic science research, highlight what clinical problem is the work relevant to), Materials and Methods, Results (for Technology Advances track provide schematic diagram of device as appropriate), Discussion, Innovation, Key Findings (present as itemized bullet list of 3-4 major findings), Acknowledgments and Funding Sources, Author Disclosure and Ghostwriting, About the Authors, Abbreviations and Acronyms, References, Tables, and Figure legends. Begin each of these sections on a separate page. The Innovation section cannot exceed 100 words and cannot be diffused. In 4-6 sentences it must summarize the current state of the field and then cite specific results reported to explain how this work helps to substantially advance the field. If the work has clinical significance, please be sure to highlight that. Do not regurgitate findings.
Following pages (Reviews): The abstract should be followed by a table of content that highlights the sections (1.0, 2.0) and sub-sections (e.g. 2.1, 2.1.1 etc). Each Review article must start with these three sections: 1.0 Scope and Significance (one paragraph on the scope of the review and its significance); 2.0 Translational Relevance (one paragraph); 3.0 Clinical Relevance (one paragraph). Each Review article must have both Relevance sections regardless of whether the article is translational (includes basic science) or clinical. Each of these paragraphs should not exceed 100 words. These sections may be followed by a Background or Overview section. The Discussion section should come next, which will encompass the majority of the text. At the end of the Review article, please include a Summary of one or two paragraphs, as well as an itemized list of Take-Home Messages. This list of messages will be presented as a sidebar in the final published version of your article, and is aimed at broad readership who may not be an expert in the subject. For example, for an article on keratinocyte cell proliferation, think of addressing a wound care nurse. Similarly, for a clinical study, think of communicating to a basic scientist who may not be aware of the clinical aspects of wound care. The Take-Home Messages will be followed by these required sections: Acknowledgments and Funding Sources, Author Disclosure and Ghostwriting, About the Authors, Abbreviations and Acronyms, References, Tables, and Figure legends.
Following pages (News and Views): The format for News and Views articles is flexible. The following sections are suggested but not required: Introduction, Clinical Problem Addressed (highlight what clinical problem is the article relevant to), Discussion, Innovation, Summary, and Key Findings or Take-Home Messages. The article must end with the sections Author Disclosure and Ghostwriting, About the Authors, Abbreviations and Acronyms, References, Tables, and Figure legends.
A complete list of abbreviations (covering text as well as illustrations) arranged in alphabetical order must be provided at the end just before the References section.
Number pages (bottom-center) consecutively; the first author’s last name should appear on each page. The source of cells utilized (species, sex, strain, race, age of donor, whether primary or established) should be clearly indicated. The source of reagents should be stated (name, city, and state within parentheses) when first cited. Publication of results is based on the principle that results must be verifiable. Authors must expect to make unique reagents available to qualified investigators either directly or through a recognized distributor. The text should be clear and concise, conforming to accepted standards of English style and usage. Unfamiliar or new terms should be defined when first used (see section on Abbreviations, Symbols, and Terminology below). Jargon, clichés, and laboratory slang should not be used.
About the Authors: After you have uploaded all the figure files in the illustration section, please upload a recent passport style photo (front face shot) of the author to whom correspondence will be addressed. Mark filenames with the name of the person. In the main manuscript, after you have listed all the figure legends, include a segment titled “About the Authors,” In this section (not to exceed 200 words), say a few words about the current position of each author. Emphasize on the first and last author.
Author Disclosure and Ghostwriting Statement
Immediately following the Acknowledgments and Funding Sources section, include a section entitled Author Disclosure and Ghostwriting. This text must be part of your actual manuscript file. In this portion of the manuscript, authors must disclose commercial associations that might create a conflict of interest in connection with submitted manuscripts and must give credit to any ghostwriters involved in the writing of the manuscript. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at www.icmje.org/index.html#conflicts for further guidance. If there is nothing to disclose, the authors must state “No competing financial interests exist. The content of this article was expressly written by the author(s) listed. No ghostwriters were used to write this article.”
DNA MICROARRAY DATA REPORTING
It is mandatory that all articles using microarray data analysis comply with the Minimum Information About Microarray Experiments (MIAME) standard (www.mged.org).
HUGO GENE NOMENCLATURE
In accordance with the HUGO Gene Nomenclature Committee (HGNC), authors should obtain approval for new human and mouse gene symbols. Additional information on gene nomenclature guidelines is available from the HGNC (www.genenames.org.)
ETHICS OF EXPERIMENTATION
The Journal endorses the principles embodied in the Declaration of Helsinki and insists that all investigations involving humans be conducted in conformity with these principles. All animal experimentation reported must be conducted in conformity with internationally accepted principles. In describing surgical procedures, the type and dosage of the anesthetic agent should be specified. Curarizing agents are not anesthetics; if these were used, evidence must be provided that anesthesia of suitable grade and duration was employed. All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. Editors are expected to reject articles in which evidence of the adherence to these principles is not apparent. They reserve the right to judge the appropriateness of the use of animals and humans in experiments. The Editors-in-Chief will adjudicate differences of opinion employing principles consistent with the content posted at: http://ethics.od.nih.gov/
ABBREVIATIONS, SYMBOLS, AND TERMINOLOGY
Include in the manuscript a list of new or special abbreviations used in the article, with the spelled-out form of the definition. Internationally accepted biochemical abbreviations such as ADP, NADH, and pi do not need to be defined; other frequently used abbreviations need only to be defined at first mention. For commonly accepted abbreviations, word usage, symbols, etc., authors are referred to Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers (6th ed., 1994). Chemical and biochemical terms and abbreviations should be in accordance with the recommendations of the IUPAC system. IUB Combined Commission on Biochemical Nomenclature. Isotope specification should conform to the IUPAC system.
SPELLING AND COMPOUNDING
Authors should follow Webster’s Third New International Dictionary for spelling and compounding.
Journal policy is against inclusion of implicit or explicit promises that future work will be published.
TABLES AND ILLUSTRATIONS
Horizontal and vertical lines should not be used in the background of any line or bar graph. It is critically important that dead space within illustration be kept to a minimum. Single column wide illustrations should not exceed 7.5 cm in width. Use font size that is not too small and clearly legible. For illustrations that must be unavoidably wider, the maximum limit is 15 cm for width. All parts (A, B, C...) of any illustration should be arranged on one page. Figure number or author name should not be printed on the face of the illustration. After you upload the illustration file, Manuscript Central will provide you with a slot to paste the figure number as well as figure legend. Figure legend should also be a part of the main body of the text.
The use of Tables is discouraged. When unavoidable, type each table single-spaced with a brief title on a separate page. The title should be brief and informative. All explanatory matter, including explanation of abbreviations, should be in footnotes, not in the title. Horizontal and vertical lines should be omitted. Use Arabic numerals to number tables. Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences. Table footnotes should be listed in order of their appearance and identified by consecutive superior lowercase letters (a, b, c, etc.).
Please follow these guidelines for submitting figures:
- Do NOT embed art files into a Word or PDF document.
- Do NOT prepare art files in Word.
- Line illustrations should be submitted at 900 dpi.
- Halftones and color should be submitted at a minimum of 300 dpi.
- Save as either TIFF or EPS files.
- Color art must be saved as CYMK–not RGB.
- Black and white art must be submitted as grayscale–not RGB.
- Bitmap or Excel files cannot be uploaded.
- All parts of one illustration must be arranged in the same file with appropriate marking of components (e.g. A, B, C...). Please name your artwork files with the submitting author’s name, i.e., SmithFig1.tif, SmithTable2.tif, etc.
Additional Information About Art Files
Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format that is suitable for print is to scan them using the below guidelines:
- All files should be scanned at 100% size.
- 300 dpi
- Final color mode: cmyk.
- Save file as .tif or .eps.
If you need directions on how to convert a Power Point slide to an acceptable format, go to www.liebertpub.com/MEDIA/pdf/ppconvert.pdf
Submit high-quality digital copies using the Advances in Wound Care Manuscript Central Online submission system. If hardcopies are required for production, authors of accepted manuscripts will be notified by the production office. Figure legends should describe experimental conditions and all abbreviations used. Electrocardiograms, kymograms, and oscillograms should be prepared so that the cross- hatched background is eliminated. To avoid problems in processing, use non-photo, blue-ruled instead of black-ruled, recording paper for the originals.
Manuscripts accepted with color figures may be published in color with a subsidy from the authors. There are two options for color publication: print + online or online only. There is no fee to publish greyscale figures in both components. Please contact AuthorBenefits@liebertpub.com for pricing options.
Authors are responsible for the accuracy of citations. References must be limited to directly pertinent published works or articles that have been accepted for publication. An abstract properly identified (Abstract) may be cited only when it is the sole source. Submitted articles can be cited in the text as “unpublished observations” but should not be included in the reference list (see below for further description). Works that have been accepted for publication in a journal should be included in the references list, indicating the journal in which it is to be published followed by “(in press)”. If you are using a referencing managing software you may use the style for Journal of Women’s Health. All references must be cited in the text using a superscript Arabic number. Arrange the reference list in numeric order as cited in the text. Note that for numbering purposes, references cited within a table or figure legend should be treated as if the citation occurred at the location where the table or figure is mentioned in the text. When there are more than six authors, list the first three followed by “et al.” Abbreviate journal names according to Medline. References should be presented in the following style: Journal articles: 1. Moldovan L, Irani K, Moldovan NI, Finkel T, Goldschmidt-Clermont PJ. The actin cytoskeleton reorganization induced by Rac1 requires the production of superoxide. Antioxid Redox Signal 1999;1:29–43. Book: 2. Sen CK, Sies H, Baeuerle PA, eds. Antioxidant and Redox Regulation of Genes, 2nd ed. San Diego, CA: Academic Press, 2000. Book section: 3. Masutani H, Ueno M, Ueda S, Yodoi J. Role of thioredoxin and redox regulation in oxidative stress response and signaling. In: Sen CK, Sies H, Baeuerle PA, eds. Antioxidant and Redox Regulation of Genes. San Diego, CA: Academic Press, 2000:298–310. Web site: Author/editor (if known) or page publisher. Title of page. Revision or copyright date, if available. URL Protocol:Site/Path/File (last access date). Example: 6. The American Gastroenterological Association. The RUC process. www.gastro.org/practice/coding/the-ruc-process (last accessed December 1, 2013). References to government technical documents should be included only when the corresponding author ensures their availability. For style of citation of these documents, congress proceedings, etc., consult recent issues of the Journal. Citations such as “unpublished observations” or “personal communication” should not be included in the reference list but may be added in the text in parentheses or as a footnote. When data from an unpublished source are given, supply the researcher’s name and institution, and the year in which the research was conducted. It is assumed that in “personal communications,” the author has secured the written permission of the person cited.
AUTHOR RESPONSE TO GALLEY PROOF
The corresponding authors must accept full responsibility to return corrected galley proof within 48 hours of receipt. Only corrections directly related to errors in typesetting will be allowed. Other changes will have to be approved by the Editor and are subject to being charged. If the corresponding author does not respond within 48 hours of receipt of the galley proof, the manuscript may be dropped from publication schedule or published as is at the discretion of the publisher. If the corresponding author expects to be out of office during the time the galley proof is expected, the publisher should be provided with an alternate contact.
The author must obtain permission whenever it is required in conjunction with the reproduction of material such as figures and tables from copyrighted material. Written permission must be obtained from the publisher of the journal or book concerned. The publication from which the figure or table is taken must be listed in the reference list. A footnote to a reprinted table or to the legend of a reprinted figure should read, “Reprinted by permission from Jones et al.,” and list the appropriate reference. All permissions listings must be shown in the manuscript—they cannot be entered on proofs. Any fees or charges that are levied by other Publishers or copyright holders are the sole responsibility of the submitting authors(s)
Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after the compendium is printed will be charged at a substantially higher rate.
Advances in Wound Care is owned and published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801–5215. Telephone: (914) 740-2100; fax: (914) 740-2101. www.liebertpub.com/wound
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email email@example.com.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email firstname.lastname@example.org or visit Liebert Open Access for more information.